Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18980920 | FCRN/HSA BINDING MOLECULES AND METHODS OF USE | December 2024 | May 2025 | Allow | 5 | 0 | 1 | No | No |
| 18817152 | PROTEIN S ANTIBODIES, METHODS OF MAKING AND USES THEREOF | August 2024 | May 2025 | Allow | 9 | 1 | 1 | No | No |
| 18773400 | VIVO GENE THERAPY USING INTRAOSSEOUS DELIVERY OF A LENTIVIRALGENE CONSTRUCT | July 2024 | June 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 18664201 | VARIANT NUCLEIC ACID LIBRARIES FOR CORONAVIRUS | May 2024 | January 2025 | Allow | 8 | 0 | 0 | Yes | No |
| 18627754 | Anti-SIRPa Antibodies and Methods of Use Thereof | April 2024 | November 2024 | Allow | 7 | 0 | 0 | No | No |
| 18601952 | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE | March 2024 | December 2024 | Allow | 9 | 2 | 0 | No | No |
| 18442779 | CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS | February 2024 | June 2025 | Allow | 16 | 1 | 0 | No | No |
| 18440437 | SPECIFIC BINDING MOLECULES | February 2024 | March 2025 | Allow | 13 | 1 | 0 | No | No |
| 18399934 | Novel Anti-Sema3a Antibodies And Uses Thereof | December 2023 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18389748 | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE | December 2023 | February 2025 | Allow | 14 | 0 | 1 | No | No |
| 18511744 | INTERFERON BETA ANTIBODIES AND USES THEREOF | November 2023 | June 2025 | Allow | 19 | 3 | 0 | No | No |
| 18506872 | PROTEIN S ANTIBODIES, METHODS OF MAKING AND USES THEREOF | November 2023 | July 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18384223 | ANTIBODIES RECOGNIZING SORTILIN | October 2023 | April 2024 | Allow | 5 | 1 | 0 | No | No |
| 18486644 | ANTI-HUMAN MASP-2 ANTIBODY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | October 2023 | August 2024 | Allow | 10 | 2 | 1 | No | No |
| 18240347 | BINDING PROTEINS TO THE HUMAN THROMBIN RECEPTOR, PAR4 | August 2023 | June 2025 | Allow | 22 | 1 | 0 | No | No |
| 18356891 | Antigen Binding Molecules Targeting Thymic Stromal Lymphopoietin (TSLP) | July 2023 | June 2024 | Allow | 10 | 1 | 1 | No | No |
| 18198600 | METHOD OF INHIBITING EXACERBATIONS OF T CELL-MEDIATED ALLOGRAFT VASCULOPATHY | May 2023 | December 2024 | Abandon | 19 | 1 | 1 | No | No |
| 18180225 | ANTI-CD3 ANTIBODIES AND USES THEREOF | March 2023 | January 2025 | Allow | 22 | 1 | 0 | No | No |
| 18173772 | ANTI-SPIKE GLYCOPROTEIN ANTIBODIES AND THE THERAPEUTIC USE THEREOF | February 2023 | March 2024 | Allow | 12 | 0 | 0 | No | No |
| 18162985 | ANTI-HUMAN PD-L2 ANTIBODIES | February 2023 | May 2025 | Allow | 27 | 1 | 1 | Yes | No |
| 17923503 | PROTEIN S ANTIBODIES, METHODS OF MAKING AND USES THEREOF | November 2022 | June 2025 | Allow | 31 | 2 | 1 | No | No |
| 17938756 | POLYPEPTIDES THAT BIND COMPLEMENT COMPONENT C5 OR SERUM ALBUMIN AND FUSION PROTEINS THEREOF | October 2022 | October 2024 | Allow | 24 | 2 | 0 | No | No |
| 17934607 | IMMUNOGENIC CD1D BINDING PEPTIDES | September 2022 | March 2025 | Abandon | 30 | 2 | 1 | No | No |
| 17933725 | ANTI-RESPIRATORY SYNCYTIAL VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE | September 2022 | December 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17871211 | SINGLE-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF | July 2022 | February 2024 | Allow | 19 | 1 | 0 | No | No |
| 17870373 | SINGLE-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF | July 2022 | January 2024 | Allow | 18 | 3 | 0 | No | No |
| 17747798 | METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER | May 2022 | August 2024 | Abandon | 27 | 2 | 1 | No | No |
| 17746768 | SARS-COV-2 SPIKE PROTEIN ANTIBODIES | May 2022 | February 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17731226 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | April 2022 | November 2023 | Abandon | 19 | 0 | 1 | No | No |
| 17707637 | Anti-SIRPa Antibodies and Methods of Use Thereof | March 2022 | January 2024 | Allow | 21 | 0 | 1 | No | No |
| 17677873 | ANTIBODIES AGAINST SIGNAL-REGULATORY PROTEIN ALPHA AND METHODS OF USE | February 2022 | November 2023 | Allow | 21 | 1 | 0 | No | No |
| 17677757 | BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV | February 2022 | February 2025 | Allow | 36 | 3 | 0 | No | No |
| 17675460 | MONOCLONAL ANTIBODY, MEASUREMENT REAGENT FOR CYTOKERATIN 18 FRAGMENT, REAGENT KIT, AND MEASUREMENT METHOD | February 2022 | January 2024 | Allow | 23 | 2 | 0 | No | No |
| 17674713 | AQUEOUS SOLUTION COMPOSITIONS FOR INCREASING STABILITY OF ENGINEERED DIMERIC PROTEINS | February 2022 | November 2024 | Abandon | 33 | 4 | 1 | No | No |
| 17670270 | METHODS OF TREATMENT WITH ANTI-FACTOR XI/XIA ANTIBODIES | February 2022 | September 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17557440 | CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS | December 2021 | November 2023 | Allow | 23 | 1 | 0 | No | No |
| 17551103 | ANTIBODY-DRUG CONJUGATE COMPRISING MODIFIED ANTIBODY | December 2021 | June 2024 | Allow | 30 | 2 | 1 | No | No |
| 17538334 | ANTIBODY FOR ENRICHMENT OF CELLS | November 2021 | July 2025 | Allow | 43 | 4 | 1 | No | No |
| 17516508 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | November 2021 | September 2023 | Allow | 22 | 1 | 0 | No | No |
| 17500537 | ANTI-GPIIB/IIIA ANTIBODIES OR USES THEREOF | October 2021 | December 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17594255 | Anti-CD40 antibodies and uses thereof | October 2021 | June 2025 | Allow | 44 | 2 | 1 | No | No |
| 17481677 | ANTI-CHI3L1 ANTIBODIES FOR THE DETECTION AND/OR TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE/ NONALCOHOLIC STEATONHEPATITIS AND SUBSEQUENT COMPLICATIONS | September 2021 | January 2024 | Allow | 28 | 2 | 0 | No | No |
| 17411979 | METHOD OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIES | August 2021 | January 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17404459 | ANTI-FACTOR IX PADUA ANTIBODIES | August 2021 | January 2024 | Allow | 29 | 2 | 0 | Yes | No |
| 17385908 | METHODS AND REAGENTS TO TREAT ALLERGY | July 2021 | April 2024 | Abandon | 32 | 2 | 0 | No | No |
| 17353402 | ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES | June 2021 | January 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17334499 | Anti-Peripheral Lymph Node Addressin Antibodies and Uses Thereof | May 2021 | August 2024 | Allow | 39 | 3 | 0 | No | No |
| 17329978 | Treatment and Prevention of Cardiovascular Disease | May 2021 | May 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17294147 | Antibodies Blocking DLL4-Mediated Notch Signalling | May 2021 | April 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17293708 | SYNERGISTIC COMBINATIONS OF METHIONINE DEPLETION AGENTS AND IMMUNE CHECKPOINT MODULATORS | May 2021 | January 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17242170 | VARIANT NUCLEIC ACID LIBRARIES FOR CORONAVIRUS | April 2021 | February 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17191764 | CORONAVIRUS NEUTRALIZING HUMANIZED ANTIBODIES AND USES THEREOF | March 2021 | April 2024 | Allow | 38 | 3 | 1 | Yes | No |
| 17254146 | ANTIDOTES TO FACTOR XA INHIBITORS | December 2020 | October 2024 | Allow | 46 | 2 | 1 | Yes | No |
| 17123656 | SELECTIVE ENRICHMENT OF ANTIBODIES | December 2020 | March 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17103672 | METHODS FOR TREATING AND/OR PREVENTING IDIOPATHIC PNEUMONIA SYNDROME (IPS) AND/OR CAPILLARY LEAK SYNDROME (CLS) AND/OR ENGRAFTMENT SYNDROME (ES) AND/OR FLUID OVERLOAD (FO) ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANT | November 2020 | March 2024 | Abandon | 40 | 1 | 1 | No | No |
| 17057867 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN PEDIATRIC PATIENTS | November 2020 | April 2025 | Allow | 53 | 3 | 0 | Yes | No |
| 17092998 | INTERFERON BETA ANTIBODIES AND USES THEREOF | November 2020 | August 2023 | Allow | 33 | 1 | 0 | No | No |
| 17051137 | IN VIVO GENE THERAPY USING INTRAOSSEOUS DELIVERY OF A LENTIVIRALGENE CONSTRUCT | October 2020 | September 2024 | Abandon | 47 | 2 | 0 | Yes | No |
| 17046695 | C-TYPE NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES | October 2020 | January 2025 | Abandon | 51 | 2 | 1 | No | Yes |
| 17065052 | Human Interleukin-2 and Anti-human Epithelial Cell Adhesion Molecule Single-Chain Antibody Fusion Protein and Application Thereof | October 2020 | November 2024 | Abandon | 50 | 2 | 1 | No | No |
| 17065368 | BIO-RESPONSIVE ADHESIVE ANTIBODY DELIVERY PLATFORM FOR IMMUNOTHERAPY AND PREPARATION METHOD THEREOF | October 2020 | December 2024 | Allow | 50 | 3 | 1 | Yes | No |
| 16982765 | METHODS AND COMPOSITIONS FOR ANTIBODY TO HIGH AFFINITY RECEPTOR FOR IGE | September 2020 | April 2024 | Allow | 43 | 2 | 1 | No | No |
| 17024094 | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE | September 2020 | April 2023 | Allow | 31 | 3 | 1 | No | No |
| 16980611 | ANTI-DENGUE VIRUS ANTIBODIES HAVING CROSS-REACTIVITY TO ZIKA VIRUS AND METHODS OF USE | September 2020 | September 2023 | Allow | 36 | 2 | 1 | No | No |
| 16968794 | CAR-T CELLS AND AUTOIMMUNE DISEASES | August 2020 | June 2025 | Allow | 58 | 4 | 1 | Yes | No |
| 16988076 | PAN-ANTIALLERGY VACCINE | August 2020 | October 2023 | Allow | 38 | 2 | 1 | Yes | No |
| 16963956 | Method for Delivering Drug to Muscle | July 2020 | April 2024 | Abandon | 45 | 3 | 1 | No | No |
| 16770840 | BISPECIFIC HIV-1-NEUTRALIZING ANTIBODIES | June 2020 | April 2024 | Allow | 46 | 3 | 0 | No | No |
| 16890380 | BISPECIFIC MOLECULES COMPRISING AN HIV-1 ENVELOPE TARGETING ARM | June 2020 | August 2024 | Allow | 50 | 2 | 1 | No | No |
| 16885797 | COMBINATION OF BROADLY NEUTRALIZING HIV ANTIBODIES AND VIRAL INDUCERS | May 2020 | October 2024 | Allow | 53 | 5 | 1 | No | No |
| 16765752 | ANTIBODIES TO CITRULLINATED PROTEINS | May 2020 | August 2023 | Allow | 39 | 4 | 1 | No | No |
| 16765274 | REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIA ANTIBODIES AND USES THEREOF | May 2020 | October 2023 | Abandon | 40 | 2 | 1 | No | No |
| 16758128 | ANTIBODY VARIANT AND ISOFORM WITH LOWERED BIOLOGICAL ACTIVITY | April 2020 | June 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16841527 | Method for Primary Prevention of Allergic Disorders During Infancy Through IgE-Class-Specific Immunosuppression | April 2020 | July 2023 | Allow | 39 | 2 | 1 | Yes | No |
| 16650889 | SPECIFIC BINDING MOLECULES | March 2020 | October 2023 | Allow | 43 | 4 | 1 | Yes | No |
| 16650385 | NEW DUAL CHIMERIC ANTIGEN RECEPTOR-T CELL WHICH CAN BE REGULATED, CONSTRUCTION METHOD THEREFOR AND USE THEREOF | March 2020 | January 2024 | Allow | 46 | 3 | 1 | No | No |
| 16608257 | COAGULATION FACTOR IX WITH IMPROVED PHARMACOKINETICS | October 2019 | October 2023 | Abandon | 47 | 3 | 1 | No | No |
| 16500251 | ANTIBODIES RECOGNIZING TAU | October 2019 | December 2023 | Allow | 50 | 3 | 1 | Yes | No |
| 16496089 | MEDICINAL COMPOSITION USABLE FOR PREVENTING AND/OR TREATING BLOOD COAGULATION FACTOR IX ABNORMALITY, COMPRISING MULTISPECIFIC ANTIGEN BINDING MOLECULE REPLACING FUNCTION OF BLOOD COAGULATION FACTOR VIII | September 2019 | November 2023 | Abandon | 50 | 3 | 1 | No | No |
| 16484813 | ENGINEERED NATURAL KILLER (NK) CELLS AND COMPOSITIONS AND METHODS THEREOF | August 2019 | October 2023 | Allow | 51 | 3 | 1 | Yes | No |
| 16481108 | Procoagulant Antibodies | July 2019 | May 2024 | Allow | 58 | 3 | 1 | Yes | No |
| 16478029 | NOVEL STABLE FORMULATION FOR FXIA ANTIBODIES | July 2019 | May 2024 | Abandon | 58 | 4 | 0 | No | Yes |
| 16435166 | COMPOSITIONS AND METHODS FOR TREATING IMMUNE THROMBOCYTOPENIA | June 2019 | September 2024 | Allow | 60 | 6 | 1 | Yes | Yes |
| 16428624 | CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) FOR THE TREATMENT OF CANCER | May 2019 | July 2024 | Abandon | 60 | 4 | 1 | No | Yes |
| 16463748 | METHODS OF TREATING HEMOPHILIC ARTHROPATHY USING CHIMERIC CLOTTING FACTORS | May 2019 | September 2023 | Allow | 52 | 3 | 1 | Yes | Yes |
| 16346896 | TREATMENT REGIMENS | May 2019 | December 2023 | Abandon | 55 | 3 | 0 | No | Yes |
| 16400595 | METHODS FOR DETECTING AND REVERSING IMMUNE THERAPY RESISTANCE | May 2019 | March 2024 | Allow | 58 | 5 | 1 | Yes | No |
| 16394223 | METHOD OF ACTIVATING DENDRITIC CELLS | April 2019 | December 2024 | Abandon | 60 | 6 | 1 | No | No |
| 16333436 | ANTI-C-MET ANTIBODIES AND ANTIBODY DRUG CONJUGATES THEREOF FOR EFFICIENT TUMOR INHIBITION | March 2019 | November 2023 | Abandon | 56 | 4 | 1 | No | No |
| 16320872 | ANTIBODIES TO ZIKA VIRUS AND METHODS OF USE THEREOF | January 2019 | July 2023 | Allow | 54 | 3 | 1 | No | No |
| 16244090 | ANTIBODY PROTAC CONJUGATES | January 2019 | December 2024 | Abandon | 60 | 5 | 1 | No | No |
| 16093495 | ANTIBODY-CONTAINING PREPARATION | October 2018 | April 2024 | Allow | 60 | 6 | 0 | Yes | No |
| 16081829 | METHODS RELATED TO ENGINEERED Fc CONSTRUCTS | August 2018 | May 2025 | Allow | 60 | 5 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner TAYLOR, LIA ELAN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner TAYLOR, LIA ELAN works in Art Unit 1641 and has examined 85 patent applications in our dataset. With an allowance rate of 67.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner TAYLOR, LIA ELAN's allowance rate of 67.1% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by TAYLOR, LIA ELAN receive 2.33 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by TAYLOR, LIA ELAN is 38 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +39.2% benefit to allowance rate for applications examined by TAYLOR, LIA ELAN. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.2% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 66.7% of cases where such amendments are filed. This entry rate is in the 87% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 34.8% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 21.1% of allowed cases (in the 93% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.